Deals Of The Week: Valeant/Eyetech, Merck/Supera Farma, Merck/Zhifei
Executive Summary
Biogen’s purchase of Stromedix completes the buy-up of independently held biotech assets in the furious competition to take the lead in idiopathic pulmonary fibrosis.